Value of epigenetic test for markers of prostate cancer affirmed in study

A commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many -- if not most -- men, a new article reports. "Often, one biopsy is not enough to definitively rule out prostate cancer," says a study researcher. "Our research finds that by looking for the presence or absence of cancer in a different way, we may be able to offer many men peace of mind without putting them through the pain, ...